{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:32:06Z","timestamp":1793763126562,"version":"4.6.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pacific Journal of Ophthalmology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.apjo.2025.100173","type":"journal-article","created":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T23:19:35Z","timestamp":1740957575000},"page":"100173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Evaluating photodynamic therapy as an adjuvant treatment for neovascular AMD: A comprehensive meta-analysis"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7290-5587","authenticated-orcid":false,"given":"Swara M.","family":"Sarvepalli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6808-9740","authenticated-orcid":false,"given":"Ishani","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kubra","family":"Sarici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunir J.","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majda","family":"Hadziahmetovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apjo.2025.100173_bib1","article-title":"Age-related macular degeneration: epidemiology, pathophysiology, diagnosis, and treatment","volume":"14","author":"Vyawahare","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.apjo.2025.100173_bib2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4068\/cmj.2023.59.3.143","article-title":"Mechanistic insight into age-related macular degeneration (AMD): Anatomy, epidemiology, genetics, pathogenesis, prevention, implications, and treatment strategies to pace AMD management","volume":"59","author":"Amini","year":"2023","journal-title":"Chonnam Med J"},{"key":"10.1016\/j.apjo.2025.100173_bib3","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1517\/14728220902942322","article-title":"Inflammation and the pathogenesis of age-related macular degeneration","volume":"13","author":"Augustin","year":"2009","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.apjo.2025.100173_bib4","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3389\/fcell.2020.612812","article-title":"Age-related macular degeneration revisited: from pathology and cellular stress to potential therapies","volume":"8","author":"Hadziahmetovic","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.apjo.2025.100173_bib5","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/S0140-6736(12)60282-7","article-title":"Age-related macular degeneration","volume":"379","author":"Lim","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.apjo.2025.100173_bib6","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1136\/bjo.2007.115501","article-title":"Types of choroidal neovascularisation in newly diagnosed exudative age-related macular degeneration","volume":"91","author":"Cohen","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100173_bib7","article-title":"Fluorescein angiography in neovascular AMD","author":"Domalpally","year":"2023","journal-title":"Rev Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100173_bib8","doi-asserted-by":"crossref","first-page":"9701","DOI":"10.1038\/s41598-019-46235-3","article-title":"Angiographic subtypes of neovascular age-related macular degeneration in Korean: A new diagnostic challenge","volume":"9","author":"Bae","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.apjo.2025.100173_bib9","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1001\/archopht.1982.01030030920003","article-title":"Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial","volume":"100","author":"Anonymous","year":"1982","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100173_bib10","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/bjo.2003.019471","article-title":"Photodynamic therapy with verteporfin is effective, but how big is its effect? Results of a systematic review","volume":"88","author":"Meads","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100173_bib11","article-title":"Anti-vascular endothelial growth factor for neovascular age-related macular degeneration","volume":"3","author":"Solomon","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.apjo.2025.100173_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100906","article-title":"Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities","volume":"82","author":"Mettu","year":"2021","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.apjo.2025.100173_bib13","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000518235","article-title":"Efficacy and safety of intravitreal aflibercept treat and extend for polypoidal choroidal vasculopathy in the ATLANTIC study: A randomized clinical trial","volume":"245","author":"Silva","year":"2022","journal-title":"Bibl Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100173_bib14","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2147\/OPTH.S386222","article-title":"Comparison of the 2-Year results of photodynamic therapy with aflibercept and aflibercept monotherapy for polypoidal choroidal vasculopathy","volume":"17","author":"Miyakubo","year":"2023","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100173_bib15","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0002-9394(01)00967-9","volume":"131","author":"Verteporfin In Photodynamic Therapy (VIP) Study Group","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100173_bib16","article-title":"A prospective pilot study of reduced fluence photodynamic therapy with Visudyne\u00ae (Verteporfin) in combination with LucentisTM (Ranibizumab) for the treatment of age-related macular degeneration","author":"Westhouse","year":"2022","journal-title":"Clin Gov"},{"key":"10.1016\/j.apjo.2025.100173_bib17","doi-asserted-by":"crossref","first-page":"46","DOI":"10.5693\/djo.01.2014.01.004","article-title":"Combined therapy (intravitreal bevacizumab plus verteporfin photodynamic therapy) versus intravitreal bevacizumab monotherapy for choroidal neovascularization due to age-related macular degeneration: a 1-year follow-up study","volume":"22","author":"Saviano","year":"2016","journal-title":"Digit J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100173_bib18","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1097\/IAE.0000000000000525","article-title":"Treatment of exudative age-related macular degeneration with ranibizumab combined with ketorolac eyedrops or photodynamic therapy","volume":"35","author":"Semeraro","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.apjo.2025.100173_bib19","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bjo.2009.159343","article-title":"Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration","volume":"94","author":"Costagliola","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100173_bib20","first-page":"3691","article-title":"Efficacy of ranibizumab combined with photodynamic therapy on wet age\u2011related macular degeneration","volume":"19","author":"Chen","year":"2020","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.apjo.2025.100173_bib21","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/IAE.0b013e3181fe54ab","article-title":"Ranibizumab monotherapy versus single-session verteporfin photodynamic therapy combined with as-needed ranibizumab treatment for the management of neovascular age-related macular degeneration","volume":"31","author":"Bashshur","year":"2011","journal-title":"Retina"},{"key":"10.1016\/j.apjo.2025.100173_bib22","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s00508-015-0772-0","article-title":"Predictors of 1-year visual outcome in OCT analysis comparing ranibizumab monotherapy versus combination therapy with PDT in exsudative age-related macular degeneration","volume":"128","author":"Weingessel","year":"2016","journal-title":"Wien Klin Woche"},{"key":"10.1016\/j.apjo.2025.100173_bib23","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000367603","article-title":"Ranibizumab plus verteporfin photodynamic therapy in neovascular age-related macular degeneration: 12 months of retreatment and vision outcomes from a randomized study","volume":"233","author":"Hatz","year":"2015","journal-title":"Bibl Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100173_bib24","doi-asserted-by":"crossref","DOI":"10.1111\/aos.12018","article-title":"Comparison of Ranibizumab monotherapy versus combination of Ranibizumab with photodynamic therapy with neovascular age-related macular degeneration","volume":"91","author":"Krebs","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100173_bib25","first-page":"1519","article-title":"A prospective pilot study comparing combined intravitreal ranibizumab and half-fluence photodynamic therapy with ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration","volume":"6","author":"Williams","year":"2012","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100173_bib26","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1185\/03007990903038616","article-title":"Visudyne in Occult CNV (VIO) study group. Verteporfin PDT for subfoveal occult CNV in AMD: two-year results of a randomized trial","volume":"25","author":"Kaiser","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.apjo.2025.100173_bib27","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.ophtha.2012.02.002","article-title":"Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration","volume":"119","author":"Larsen","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2025.100173_bib28","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1016\/j.ophtha.2009.04.032","article-title":"Photodynamic therapy and intravitreal triamcinolone for neovascular age-related macular degenerationa randomized clinical trial","volume":"116","author":"Maberley","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2025.100173_bib29","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00417-010-1343-8","article-title":"Photodynamic therapy alone versus combined with intravitreal bevacizumab for neovascular age-related macular degeneration without polypoidal choroidal vasculopathy in Japanese patients","volume":"248","author":"Hara","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100173_bib30","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/j.ophtha.2006.04.039","article-title":"Photodynamic therapy with intravitreal triamcinolone in predominantly classic choroidal neovascularization","volume":"113","author":"Arias","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2025.100173_bib31","first-page":"602","article-title":"Photodynamic therapy and high- dose intravitreal triamcinolone to treat exudative age-related macular degeneration","volume":"26","author":"Ruiz-Moreno","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.apjo.2025.100173_bib32","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.ophtha.2007.03.006","article-title":"Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration","volume":"114","author":"Lazic","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2025.100173_bib33","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1016\/j.ophtha.2007.02.013","article-title":"Triamcinolone acetonide as adjunctive treatment to verteporfin in neovascular age-related macular degeneration","volume":"114","author":"Chaudhary","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2025.100173_bib34","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/eye.2010.84","article-title":"A randomized prospective double-masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration","volume":"24","author":"Vallance","year":"2010","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.apjo.2025.100173_bib35","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1001\/archopht.117.10.1329","volume":"117","year":"1999","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100173_bib36","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1001\/archopht.123.4.448","article-title":"Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-Year results of a randomized clinical trial","volume":"123","author":"Visudyne in minimally classic choroidal neovascularization (VIM) study group","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100173_bib37","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.ophtha.2012.02.003","article-title":"Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration","volume":"119","author":"Kaiser","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2025.100173_bib38","first-page":"541","article-title":"Combination of ranibizumab with photodynamic therapy vs ranibizumab monotherapy in the treatment of age-related macular degeneration: a systematic review and meta-analysis of randomized controlled trials","volume":"7","author":"Si","year":"2014","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100173_bib39","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.pdpdt.2018.05.002","article-title":"Photodynamic therapy in combination with ranibizumab versus ranibizumab monotherapy for wet age-related macular degeneration: A systematic review and meta-analysis","volume":"22","author":"Su","year":"2018","journal-title":"Photo Photo Ther"},{"key":"10.1016\/j.apjo.2025.100173_bib40","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajo.2017.05.014","article-title":"Relationship between visual acuity and retinal thickness during anti-vascular endothelial growth factor therapy for retinal diseases","volume":"180","author":"Ou","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100173_bib41","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/eye.2013.107","article-title":"Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature","volume":"27","author":"Ghasemi Falavarjani","year":"2013","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.apjo.2025.100173_bib42","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2174\/138945011794182746","article-title":"Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration","volume":"12","author":"Becerra","year":"2011","journal-title":"Curr Drug Targets"}],"updated-by":[{"DOI":"10.1016\/j.apjo.2026.100347","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000}},{"DOI":"10.1016\/j.apjo.2026.100347","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000}}],"container-title":["Asia-Pacific Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162098925000404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162098925000404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T08:59:52Z","timestamp":1742288392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162098925000404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2162098925000404"],"URL":"https:\/\/doi.org\/10.1016\/j.apjo.2025.100173","relation":{},"ISSN":["2162-0989"],"issn-type":[{"value":"2162-0989","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating photodynamic therapy as an adjuvant treatment for neovascular AMD: A comprehensive meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Asia-Pacific Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apjo.2025.100173","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of Asia-Pacific Academy of Ophthalmology and Academy of Asia-Pacific Professors of Ophthalmology.","name":"copyright","label":"Copyright"}],"article-number":"100173"}}